MetaCap

Purple Biotech (PPBT) vs XORTX Therapeutics (XRTX)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

XORTX Therapeutics is the larger company by market cap ($1.9 million vs $1.9 million), about 1.0 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

PPBT+4.45%XRTX-51.92%
+21%-17%-55%
Oct 7, 20261 yearNov 20, 2026
PPBT+14.66%XRTX-40.50%
+26%-9%-44%
Oct 5, 20265 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

PPBT versus XRTX key metrics
MetricPPBTXRTX
Share price$1.53$0.839
Market cap$1.86M$1.88M
1-day change-4.09%-5.73%
Forward P/E—1.05
EPS (TTM)$-47.64$-2.09
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Net income (latest FY)$-26.39M—
52-week high$8.90$3.60
52-week low$0.91$0.81
Distance from 52-week high-82.87%-76.69%
Analyst consensusnone—
Avg. price target upside+1014.75%—
Average volume1.26M776.48K
Shares outstanding1.22M2.25M
Employees10—
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

About Purple Biotech

PPBT stock →

Purple Biotech Ltd., a clinical-stage company, focuses on developing therapies to overcome tumor immune evasion and drug resistance for cancer patients in the United States. Its oncology pipeline includes CM24, a humanized monoclonal antibody that blocks the interactions of carcinoembryonic antigen related cell adhesion molecule 1 as a combination therapy with anti-PD-1 checkpoint inhibitors, which is in Phase 2 clinical trial for the treatment of pancreatic ductal adenocarcinoma; NT219, a small molecule that targets and inhibits insulin receptor substrate 1 and 2, and signal transducer and activator of transcription, which is in Phase 2 clinical trials for the treatment recurrent and/or metastatic squamous cell carcinoma of the head and neck cancer or colorectal adenocarcinoma; and CAPTN-3 - IM1240 and IM1305, multi-valent antibody designed to activate anti-tumoral immune response against TAA positive tumors, which is in preclinical stage.

Health Care · Biotechnology: Pharmaceutical Preparations · 10 employees

About XORTX Therapeutics

XRTX stock →

XORTX Therapeutics Inc., a late-stage clinical pharmaceutical company, engages in the development and commercialization of therapies to treat hyperuricemia related diseases in Canada. It develops XRx-026, which is in Phase III for the treatment of gout; XRx-008, which is in Phase II for the treatment of autosomal dominant polycystic kidney disease; XRx-101, which is in Phase II for the treatment of acute kidney injury associated with respiratory virus infection, including sepsis and coronavirus; and XRX-225, which is in preclinical stage for the treatment of type 2 diabetic nephropathy, as well as VB4-P5, a program for the treatment and prevention of fibrosis in the kidney.

Health Care · Biotechnology: Pharmaceutical Preparations

PPBT vs XRTX FAQ

Which is bigger, Purple Biotech or XORTX Therapeutics?

XORTX Therapeutics (XRTX) is larger, with a market capitalization of $1.88M compared with $1.86M for Purple Biotech (PPBT).

Are Purple Biotech and XORTX Therapeutics in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons